Xenetic Biosciences, Inc.
$3.4
▲
6.74%
2026-04-21 10:20:02
www.xeneticbio.com
NCM: XBIO
Explore Xenetic Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$7.09 M
Current Price
$3.4
52W High / Low
$13.93 / $1.9
Stock P/E
—
Book Value
$3.23
Dividend Yield
—
ROCE
-38.33%
ROE
-40%
Face Value
—
EPS
$-1.58
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
2
Beta
2.21
Debt / Equity
—
Current Ratio
8.32
Quick Ratio
8.32
Forward P/E
-4.64
Price / Sales
2.36
Enterprise Value
$-0.87 M
EV / EBITDA
—
EV / Revenue
-0.29
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Disc Medicine, Inc. | $71.41 | — | $2.74 B | — | -30.64% | -35.86% | $99.5 / $39.2 | $19.52 |
| 2. | Zentalis Pharmaceuticals, Inc. | $4.03 | — | $301.33 M | — | -57.45% | -49.54% | $6.95 / $1.13 | $3.13 |
| 3. | AtaiBeckley Inc. | $4.9 | — | $1.47 B | — | -76% | -3.9% | $6.75 / $1.29 | $0.61 |
| 4. | Nektar Therapeutics | $100.35 | — | $2.87 B | — | -57.64% | -2.18% | $109 / $7.99 | $4.41 |
| 5. | Coherus Oncology, Inc. | $1.99 | 1.76 | $295.28 M | — | -155.52% | -473.47% | $2.62 / $0.71 | $0.5 |
| 6. | Soleno Therapeutics, Inc. | $52.67 | 130.16 | $2.72 B | — | 2.98% | 6.01% | $90.32 / $29.43 | $8.61 |
| 7. | PTC Therapeutics, Inc. | $72.32 | 8.72 | $5.95 B | — | 44.37% | -104.75% | $87.5 / $35.95 | $-2.52 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.77 M | 1.03 M | 0.59 M | 0.59 M | 0.65 M | — |
| Operating Profit | -0.62 M | -0.54 M | -0.72 M | -0.94 M | -1.1 M | — |
| Net Profit | -0.58 M | -0.51 M | -0.69 M | -0.9 M | -1.05 M | — |
| EPS in Rs | -0.25 | -0.22 | -0.3 | -0.39 | -0.46 | -0.28 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.98 M | 2.5 M | 2.54 M | 1.71 M |
| Operating Profit | -2.83 M | -4.2 M | -4.52 M | -6.72 M |
| Net Profit | -2.68 M | -3.96 M | -4.13 M | -6.55 M |
| EPS in Rs | -1.17 | -1.73 | -1.8 | -2.86 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 8.36 M | 6.9 M | 10.61 M | 14.72 M |
| Total Liabilities | 0.97 M | 0.89 M | 0.81 M | 1.07 M |
| Equity | 7.4 M | 6.01 M | 9.8 M | 13.65 M |
| Current Assets | 8.05 M | 6.59 M | 9.59 M | 13.65 M |
| Current Liabilities | 0.97 M | 0.89 M | 0.81 M | 1.07 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -2.29 M | -2.82 M | -4.11 M | -4.65 M |
| Investing CF | — | — | 0 M | -0.5 M |
| Financing CF | 4 M | 0 M | — | 0 M |
| Free CF | -2.29 M | -2.82 M | -4.11 M | -5.15 M |
| Capex | — | — | — | -0.5 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -1.56% | 48.8% | — | — |
| Earnings Growth % | 4.22% | 36.9% | — | — |
| Profit Margin % | -158.39% | -162.78% | -383.87% | — |
| Operating Margin % | -168.16% | -177.79% | -393.57% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -168.16% | -177.79% | -391.98% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2023-05-15 | 1:0.1 |